Ads
related to: multiple myeloma- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Contact a Representative
For Questions and Information
About This Treatment
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Primary and Subgroup Data
Search results
Recent FDA Committee Vote Could Speed Multiple Mye | Newswise
Newswise· 1 day agoA U.S. Food and Drug Administration committee voted unanimously in April to approve a new clinical...
Congress to evaluate how to lower prescription prices by increasing competition
WFXT via Yahoo News· 8 hours ago“My doctors have me on a four drug combination with a list price of more than one million dollars a...
AI Tool Shows Promise in Cancer Therapy Matching, but More Training Data Needed
GenomeWeb News· 10 hours agoA machine learning-based approach could enable the use of computationally intensive single-cell transcriptomic analysis to predict cancer patients' responses to treatment, if researchers can ...
Arcellx shares target raised by Stifel on study design By Investing.com
Investing.com· 7 days agoThe adjustment follows the company's announcement regarding the design of a phase 3 study for...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 12 hours agoLeading AstraZeneca’s efforts is a dual-acting therapy that hits a protein active on multiple ...
Doubt Cast on MGUS-Autoimmune Disease Link
MedPage Today· 2 days agoContrary to earlier studies, the not-entirely-rare condition known as monoclonal gammopathy of undetermined significance (MGUS) did not appear to raise...
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the...
WPRI Providence· 2 days agoHaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg ...
1 million veterans have received health benefits for toxic exposure through PACT Act
Stars and Stripes· 23 hours agoThe delivery of benefits to veterans exposed to burn pits and other toxins from military service...
Earnings call: Autolus Therapeutics Reports Progress and Financials for Q1 2024
Investing.com· 4 days agoIn a recent earnings call, Autolus Therapeutics (NASDAQ: AUTL ), a biopharmaceutical company...
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Zacks via Yahoo Finance· 6 days agoBristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy...